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Depression is a complex mental health disorder, resulting in a high degree of disability. 
Since symptom constellation, course, and outcome are heterogeneous in these 
patients, current research initiatives are striving to establish stratified diagnostic and 
treatment approaches. In the past two decades, Dirk Hellhammer and his team 
introduced Neuropattern, a new diagnostic concept, which is based on conceptual 
endophenotypes of the stress response network. We explore how to use this concept in 
clinical practice in order to ultimately determine whether it brings any value over 
standard care. In view of the novelty of the concept and the difficulties dealing with such 
a concept at a practical level, it was necessary to initiate an exploratory study to 
determine key factors for planning future clinical trials.  
We report results and learning from an exploratory single-site study investigating the 
use and potential benefits of Neuropattern in standard care. Inpatients (ICD-10 
diagnosis F32, F33; N=178) were allocated to either treatment as usual (standard 
group, SG) or a novel Neuropattern oriented exploratory treatment (intervention group, 
IG). Symptom severity was assessed with psychometric tests at admission to hospital, 
during the first six weeks, and upon discharge from the hospital. In addition, direct and 
indirect costs were assessed for the 3-month-intervals prior to and after the hospital 
stay.  
Compared to the SG, depression scores of patients in the IG showed a faster decline 
once psychotherapeutic and pharmacological treatment were based on an 
individualized explanatory model. The patients in the IG with an F33 diagnosis showed 
a more pronounced reduction of depression severity during the stay in the hospital and 
a stronger and quicker reduction of general symptom severity. Comparing the average 
depression scores at the start of the study and after six weeks, a decline in symptoms 
was observed for all Neuropatterns.  
Some limitations of the study have to be mentioned: The study was not blinded, was 
single-site, included highly depressed inpatients only, and was conducted for no longer 
than 8 months. The results highlight some important points regarding taking the 
Neuropattern approach to the bedside and researching its efficacy and effectiveness to 
support personalized treatments in clinical care.  
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1.     Introduction 
 
Depression is one of the most common mental health problems with a 12-month 
prevalence in the adult German population estimated at 8.2% (Jacobi et al., 2015) and 
the lifetime prevalence at about 17% (Jacobi et al., 2004). Depression occurs more 
frequently in women than in men and can begin at any age, but is most prevalent 
between ages 18 and 29 (Busch et al., 2013). The World Health Organization (WHO) 
estimated that major depression caused more disability worldwide than ischemic heart 
disease or cerebrovascular disease and may soon represent the most severe illness 
worldwide (WHO, 2008). In addition to the symptoms, depression causes significant 
loss of health-related quality of life (Williams et al., 2016) and entails high direct costs 
(e.g., cost of physicians, drug treatment, and psychotherapy) and indirect costs (e.g., 
sick leave; Andlin-Sobocki and Wittchen, 2005; Cuijpers et al., 2007, 2010; Layard, 
2006; Thomas and Morris, 2000; Luppa et al., 2007; Olesen et al., 2012). 
 
However, it is not simple to diagnose and treat depression, given the complexity and 
heterogeneity of symptoms: A variety of different symptoms (Fried, 2017) range along a 
continuum without clear-cut points (Melzer et al., 2002), and complex comorbidity with 
somatic and psychological disorders as well as different etiologies make the diagnostic 
process and individualized treatment difficult and time-consuming.  
 
Different strategies have been developed to improve personalized diagnostic and 
therapeutic treatments. The National Institute of Mental Health (NIHM) of the United 
States launched the “Research Domain Criteria” (RDoC): “RDoC´s ultimate goal is 
precision medicine for psychiatry – a diagnostic system based on a deeper 
understanding of the biological and psychosocial basis of a group of disorders that is 
unambiguously among the most disabling disorders in medicine“ (Insel, 2014, p. 396). 
In the long run, RDoC intends to establish a brain-based classification of mental illness, 
by detecting and discriminating types of pathogenetic dysregulation which would 
improve personalized treatments. It is currently a framework for organizing research, 
starting with five domains of functioning (negative valence systems, positive valence 
systems, cognitive systems, systems for social processes, and arousal/regulatory 
systems). The RDoC matrix documents information for each psychopathological 
construct and sub-construct with respect to genes, molecules, cells, circuits, physiology, 
behavior, and self-reports (Casey et al., 2013; Cuthbert and Kozak, 2013). 
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Another strategy towards personalized medicine was proposed by the National 
Research Council of the US National Academies of Sciences, entitled “A Framework for 
Developing a New Taxonomy of Disease” (NRC, 2011), which assumes that the 
successful translation of basic research to clinical care requires a knowledge network 
that provides a fruitful exchange between basic and clinical research. This knowledge 
network generates subgroups mainly from individual characteristics of the genome, 
epigenome, microbiome, and exposome and the patient´s signs and symptoms. Thus, 
the knowledge network has its main focus on the physiological and environmental 
functions that are relevant for pathology. Both kinds of data mining may ultimately 
generate valid endophenotypes that can predict the prognosis or treatment response for 
an individual patient and which may replace inadequate symptom-oriented descriptive 
procedures (Miller and Rockstroh, 2013). 
 
1.1 Neuropattern  
 
For mood disorders, it is not yet foreseeable, if, when, and to which extent such 
strategies will become applicable for clinical routine (Maj, 2016a). Maj (2016b) recently 
addressed the need for a conceptual framework, which takes the tremendous 
complexity and heterogeneity of a multiplicity of biological, intrapsychic, interpersonal 
and sociocultural factors into account. Such a strategy, called Neuropattern, was 
developed by Hellhammer and his group since 1999 (Hellhammer et al., 2018).  
 
Briefly, Neuropattern focuses on dysregulations of three subsystems of the stress 
response network in the brain: the (1) ergotropic systems, which facilitate task-directed 
mental and physical activities, mainly represented by adrenergic functions, (2) 
trophotropic systems, which promote rest, regeneration, and reconstitution of energy 
stores, primarily including brain serotonergic and parasympathetic functions, and (3) 
glandotropic systems, which organize the behavioral adaptation to stress and support 
the energy supply for the brain, essentially represented by the hypothalamic-pituitary-
adrenal (HPA) axis (for details see Hellhammer et al., 2018; Hellhammer et al., 2012; 
Hellhammer and Hellhammer, 2008).  
 
Each dysregulation of these subsystems is conceptualized by a characteristic pattern of 
psychological, biological, and symptom measures.  
 
So far 13 patterns have been operationalized: CRF(corticotropin releasing factor)- 
hypoactivity, CRF-hyperactivity, CRF-hyperreactivity, NA(noradrenaline)-hypoactivity, 
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NA-hyperactivity, NA-hyperreactivity, sympathetic hypoactivity, sympathetic 
hyperreactivity, serotonin-hypoactivity, serotonin-hyperreactivity, cortisol-hypoactivity, 
cortisol-hyperactivity, and GR(glucocorticoid receptor)-resistance. For example, CRF-
hypoactivity is expected to be associated with lowered cortisol levels upon awakening, 
lethargy as a psychological characteristic, and hypersomnia as the symptomatic 
variable. Evidence for the psychopathological relevance of a Neuropattern is fulfilled, 
once a patient presents a sufficient amount of priori defined criteria of each of these 
three categories (Contreras et al., 2018). Table 1 gives an overview of the number of 
psychological, biological, and symptomatic variables and the corresponding examples 





The combination of measures of individual differences reflect the current knowledge on 
the biological, psychological, and symptom concomitants of such dysregulations, as 
well as on relevant modulators such as early adversity, genetic and epigenetic 
determinants (Hellhammer and Hellhammer, 2008). Hypotheses on such dysregulations 
are considered “conceptual endophenotypes”. In contrast to empirically 
endophenotypes, conceptual endophenotypes are hypothetical and are of heuristic 
value. Their reliability and validity is continuously elaborated in an iterative process 
between basic and clinical research. It is expected that such kind of information would 
already help to improve the competence of the physician to individualize treatments. 
This new research strategy has recently been published in detail by Hellhammer, 
Meinlschmidt and Pruessner (2018). 
 
1.2 Aim of the study  
 
The aim of the following study was to explore possible benefits of applying 
Neuropattern diagnostics in a hospital for behavioral medicine in depressed patients, as 
previously shown in a comparable study in inpatients with various mental disorders and 
high somatization (Hero et al., 2012). In a practice-based exploratory approach, 
therapeutic success was compared between a group of depressed patients who 
received Neuropattern diagnostics (intervention group, IG) in addition to the hospital’s 
standard treatment, and a group which received the hospital’s standard treatment only 
(standard group, SG). We were interested to explore if the application of Neuropattern 
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results in (1) a quicker reduction in unspecific and specific symptom severity during the 
first six weeks of the hospital stay (longitudinal assessment); (2) a stronger decrease in 
unspecific and specific symptom severity in the time between admission to the hospital 
and discharge from hospital (pre-post assessment); and (3) a stronger decrease in the 
number of consultations with the doctor and days of sick leave (indicative of lower direct 
and indirect costs) in the 3-month follow-up period.  
 
We further explored whether and which conceptual endophenotypes contribute to the 
therapeutic success of the treatment. We were interested in understanding whether the 
Neuropattern concept would add any value in clinical practice compared to the 
treatment as usual. The novelty of such a concept and the difficulties in dealing with it at 
a practical level required initiating an exploratory study in order to determine the key 
factors to take into account in future clinical trials. The study protocol was approved by 
the ethical committee of the respective Chamber of Physicians (Landesärztekammer 
Hessen, Reg. Nr. FF 99/2010). 
 
 
2.       Materials and methods 
 
2.1 Study design, location and subjects  
 
We conducted an open-label, non-registered naturalistic exploratory study. The study 
was implemented within the daily routine of a hospital for behavioral medicine in central 
Germany (North Hesse). Here, all patients (privately insured) were screened on arrival. 
Inclusion criteria were a diagnosis of ‘depression’ (ICD-10 F32, F33; including 
comorbidity) and age 18-70 years. Of these, n=56 did not fulfill diagnostic criteria, n=2 
were too old, and n=47 refused to apply Neuropattern diagnostics based on personal 
reasons (see Fig. 1). After admission to the hospital, written informed consent was 
obtained from 178 German-speaking patients.  
 
The patients were allocated to either Neuropattern diagnostics (IG) or the standard 
treatment provided by the hospital (SG). A list with alternating treatment assignments 
was held in the hospital administration. When a patient met the inclusion criteria, the 
clinical investigator called the hospital administration and was provided with the 
allocation for his patient. The administrator was blind to the characteristics of the patient 
and the clinical investigator was blind to the state of the list.  
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Both groups received a complex therapy program consisting of diagnosis-specific as 
well as unspecific group therapy and individual psychotherapy based on behaviour 
therapy, progressive muscle relaxation, art therapy, vocational therapy, sports and 
exercise therapy, psychoeducation, and regular ward rounds. In addition, psychophar-
macological treatment was delivered, based on either the clinician’s preferred 
medication or the medication that the patient had been prescribed previously. The IG 
additionally received Neuropattern diagnostics. Changes to the treatment are described 
separately below. The psychoeducation for the SG followed a general diathesis 
(vulnerability) stress model (Ingram and Luxton, 2005). 
 
No patient was free of medication at the beginning of the evaluation. Two patients 
dropped out before the intervention started, and 23 patients did not return 
questionnaires at the follow-up 3 months after the intervention. No further drop-outs 
were documented at the second follow-up 6 months after the intervention (see Fig. 1 for 
flow chart).  
___________________ 
Figure 1  
___________________ 
 
After applying the exclusion criteria and drop-out occurring during the study, the study 
population comprised 131 inpatients diagnosed with depression (ICD-10 F32, F33), 
who were treated for a period of at least 6 weeks. In total, 69 women and 62 men took 
part in the study. Sociodemographic data are reported in Table 2. Patients in this study 
were largely in their late forties, had a better than general economic status, and stayed 
in the hospital for about 2 months. Although patients had to fulfil the criteria for either 
ICD-10 F32 or F33, about half of the patients (48%) fulfilled the criteria for at least one 
additional diagnosis. At the start of the study period, the two groups of patients did not 





2.2   Assessment 
 
The Brief Symptom Inventory (BSI; Derogatis, 1992; Franke, 2002) was used to assess 
the general symptom severity at the time of a patient´s admission to the hospital and at 
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discharge from hospital. The Beck Depression Inventory (BDI; Beck et al., 1961; 
Hautzinger et al., 1995) was used to assess the symptom specific severity of 
depression at these time points as well. The Symptom Check List, Short Version 9 
(SCL-K9; Klaghofer and Brähler, 2001; Prinz et al., 2013), a short version of the 
Symptom Check List SCL-90-R, and the German version of the Hamilton Rating Scale 
for Depression (HAMD; Hamilton, 1960) were administered weekly by trained research 
assistants during the first six weeks of the hospital stay. An evaluation questionnaire 
was used to assess the direct and indirect costs (days of sick leave and visits to 
physicians during the past three months) at admission to the hospital and at three 
months after discharge from hospital.  
 
The following questionnaires and assessments were administered to the patients of the 
IG only: The Neuropattern Questionnaire (NPQ) – Anamnesis (NPQ-A; Hellhammer, 
2009a) is an anamnestic questionnaire for the physician to collect information about 
physiological diseases and anthropometric data. The NPQ – Symptom List (NPQ-S; 
Hellhammer, 2009b) collates stressful life events, emotional and cognitive stress 
responses, and exhaustion states. The NPQ – Patient Questionnaire (NPQ-P; 
Hellhammer, 2009c) collects perceived psychological and symptomatic traits associated 
with dysregulation of the stress response network. The NPQ – Pre-/Post-natal Stress 
Questionnaire (NPQ-PSQ; Hellhammer, 2009d) is a questionnaire to inquire pre-, peri- 
and postnatal adverse events during early development that are considered relevant for 
the pathogenesis of health disorders. Finally, the Patient Health Questionnaire (PHQ; 
Löwe et al., 2002; Spitzer et al., 1999) is a valid screening test of psychiatric disorders. 
 
The information obtained with these questionnaires and biomarkers (salivary cortisol 
levels at 0, 30, 45 and 60 min after awakening and at 15:00 hrs and 20:00 hrs; low-dose 
(0.25 mg) dexamethasone suppression test (DST); measures of heart rate variability 
before sleep, overnight, and after awakening) was used to assign patients in the IG to 
the 13 conceptual endophenotypes in accordance with the procedures described by 
Hellhammer and Hellhammer (2008).  
 
2.3   Neuropattern diagnostic and treatment recommendations 
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As described in more detail in Hellhammer et al. (2018), each of the 13 Neuropatterns 
is a priori defined by biological, psychological, and symptom measures. To qualify for a 
Neuropattern, a patient has to fulfill a given number of criteria from these three 
categories.  
 
Thus, a patient can qualify for one or more Neuropatterns. A computerized analysis 
results in a report. For each possible constellation, the automatic report comes with a 
disease model (“stress triangle”) and suited psychological and pharmacological 
treatment recommendations.  
 
After the diagnostic phase, patients of the IG received an individualized explanatory 
model of the dysfunctions from which psychotherapeutic and pharmacological 
recommendations were derived. The procedure explaining the Neuropattern diagnostics 
as well as the Neuropattern-based disease model was standardized and documented in 
the study protocol. For the explanatory model, we used a picture to illustrate 
dysregulations of the trophotropic serotonergic and parasympathetic systems, the 
ergotropic noradrenergic and sympathetic systems, and the glandotropic systems, 
respectively. In easy words and illustrations, the patients were informed about 
dysfunctions of the stress response network by a trained research assistant: advice was 
provided about what can be done to rebalance the three systems.  
 
2.4   Data analysis  
 
Statistical analyses were performed using the SPSS statistical software package 
(PASW 17, Chicago, Illinois, USA). Data are presented according to the intent-to-treat 
principle with means ± standard error (SE) and 95% confidence intervals (95% CI). 
Variables for intangible costs were measured either two (BDI, BSI) or six times (SCL-
K9, HAMD). We performed two 2 × 2 × 2 and two 2 × 2 × 6 repeated-measures 
analyses of variance (ANOVA) to account for differences in intangible costs over time 
(BDI, BSI, SCL-K9, HAMD) between treatment and control group as well as patients 
with diagnoses for a depressive episode (ICD-10 F32) or a recurrent depressive 
disorder (ICD-10 F33). For each repeated-measures ANOVA, we estimated group × 
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time, diagnoses F32/33 × time and group × diagnoses F32/33 × time interaction effects 
to evaluate potential differences in change over time with respect to group affiliation and 
diagnosis F32/33. 
 
In case of significant interaction effects between time and group (or ICD-10 diagnoses 
F32/33), we performed contrast analyses for repeated-measures to determine the 
specific time span, in which SCL-K9 or HAMD scores developed differently between 
groups (or diagnoses F32/F33). In case of significant interaction effects between time, 
group and diagnoses F32/F33, we performed repeated-measures ANOVAs post-hoc for 
both ICD-10 F32 and F33 patients separately to estimate potential differences in the 
ICD-10 F32 and the F33 subsamples. 
 
Greenhouse-Geisser corrected degrees of freedom (df) are reported for F-statistics 
whenever sphericity of repeated measurements was violated. Potential relationships 
with the Neuropattern diagnostic were explored with descriptive analyses.  
 
The variables ʽconsultations with the doctorʼ (direct costs) and ʽdays of sick leaveʼ 
(indirect costs) did not meet the necessary assumptions to perform parametric testing. 
Thus, difference values were calculated (baseline value minus follow-up assessment). 
As the assumptions for parametric testing were also violated for these difference 
variables, Mann Whitney U-tests were used on difference values to test for group 
differences in direct and indirect costs. 
 
 
3.     Results 
 
3.1    Comparison of intervention and standard group  
 
Repeated-measures ANOVAs showed significant changes over time in the direction of 
significant lower values for BDI, BSI, HAMD, and SCL-K9 (all p<.001). We found no 
significant main effect for group (IG/Neuropattern vs. SG), or ICD-10 diagnosis F32/33 
(all p≥.05). Furthermore, repeated-measures ANOVAs revealed a significant time × 
group interaction for HAMD scores indicating faster decreases in HAMD scores in the 
IG (Neuropattern) as compared to the SG (Fig. 2). Contrast analyses for repeated 
measures showed these decreases to be significant in the time span between t1 and t2 
(F (1, 95)=6.08, p=.015, partial-ƞ2=0.06). Moreover, we found significant time × group × 
diagnosis F32/33 interactions for BDI, BSI, and SCL-K9 scores (Fig. 3). Test statistics 
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of these results are summarized in Table 4. Contrast analyses for repeated measures 
of SCL-K9 scores show these decreases to be significant in the time span between t2 
and t3 (F (1, 97)=4.55, p=.035, partial-ƞ2=0.045). Post-hoc repeated-measures 
ANOVAs for either ICD-10 F32 or F33 patients revealed significant time × group 
interactions only in the F33 (BDI: F (1, 57)=3.57, p=.064, partial-ƞ2=0.059; BSI: F (1, 
57)=5.09, p=.028, partial-ƞ2=0.082; SCL-K9: F (3.16, 142.06)=2.66, p=.047, partial-
ƞ2=0.056) but not in the F32 subsample (BDI: F (1, 61)=2.02, p=.160; BSI: F (1, 
61)=1.59, p=.213; SCL-K9: F (3.26, 169.57)=0.72, p=.551). 
___________________ 






With respect to ʽconsultations with the doctorʼ and ʽdays of sick leaveʼ, Mann-Whitney U 
tests revealed no significant differences between IG (Neuropattern) and SG neither for 
baseline (ʽconsultations with the doctorʼ: U=1778, Z=0.84, p=.399; ʽdays of sick leaveʼ: 
U=1846.5, Z=0.66, p=.513) nor for difference values for baseline minus the three 
month catamnesis after discharge from the hospital (ʽconsultations with the doctorʼ: 
U=1332.5, Z=0.81, p=.419; ʽdays of sick leaveʼ: U=1204.5, Z=1.59, p=.112). 
 
3.2  Results of the exploratory analyses  
 
As we found a positive effect of Neuropattern for the whole IG with regard to the 
reduction of HAMD-scores, it was explored which of the Neuropatterns contributes most 
to this therapeutic effect.  
 
Table 5 shows the total scores for the HAMD t0 and t5 for the various Neuropattern. 
The different Neuropatterns occur in varying numbers: the most frequent Neuropatterns 
are serotonin-hyperreactivity and serotonin-hypoactivity, no patient qualified for cortisol-
hyperactivity. 
___________________ 
Table 5  
___________________ 
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Comparing the mean scores of the HAMD at t0 and at t5 a decline can be observed 
across all the various Neuropatterns. This result is true for the whole group of patients 
(Table 5) as well as for the subgroups diagnosed ICD-10 F32 and/or F33; the results 
calculated separately for these two groups are not shown here as they were essentially 
the same as for the total group.   
 
 
4.  Discussion 
 
In this practice-based exploratory study, we set out to evaluate the effect of providing a 
cohort of inpatients (ICD-10 F32, F33) with an individualized explanatory model of 
dysfunction based on Neuropattern (Hellhammer et al., 2012).  
 
4.1  Primary results 
 
The results of this study show that depression scores declined more rapidly in the 
whole IG compared to the SG during the hospital stay. The results are in line with a 
previous Neuropattern study in inpatients with various mental disorders and high 
somatization which also showed a significantly greater improvement for the intervention 
group in self-rating assessments on symptom severity (Hero et al., 2012). For the F33 
subgroup of patients of the IG, we found a more pronounced reduction of depression 
severity during the stay in the hospital, and a stronger and quicker reduction of general 
symptom severity. However, our analyses revealed no effect of Neuropattern on the 
reduction of ʽdays of sick leaveʼ and ʽconsultations with the doctorʼ after discharge from 
hospital. 
 
Future studies should explore in more detail the causal pathways leading to this finding. 
Our results suggest a role of the individualized explanatory model of dysfunction from 
which treatment recommendations were derived. Potential pathways that might lead to 
such a finding are (1) a more targeted application of evidence-based intervention 
techniques during the hospital stay as outlined above; (2) a shift to a more active 
engagement and empowerment of individual patients to tackle their daily lives more 
effectively and with a feeling of control (Tew et al., 2012); (3) other pathways that have 
been suggested to be relevant in interventions targeting lifestyle and behavioral 
changes (Clarke et al., 2015; Serrano-Ripoll et al., 2015; Pampallona et al., 2002); and 
(4) pharmacological treatment recommendations, which should best be monitored in 
single case studies (Smith, 2012). The particular challenge here is to have administered 
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a substance recommended by Neuropattern diagnostics that may be breaking with 
clinical routine (Boyle, 2013). In clinical routine, the selection of medication 
is rather oriented on patients’ psychopathology and the medication’s side effects.  
 
Krishnan (2015) recently compared the approach of the National Research Council 
(NRC) with common taxonomies, the Diagnostic and Statistical Manual of Mental 
Disorders, and the Research Domain Criteria of the National Institute of Mental Health. 
The NRC considers a knowledge network necessary to understand the biology and 
underlying causes of psychiatric diseases, and to successfully discriminate subgroups 
for a new taxonomy. Studies applying conceptual endophenotypes are likely to add 
relevant data to such a knowledge network. An obvious advantage of Neuropattern is 
the utility of this system. Once validated, some conceptual endophenotypes may prove 
predictive value of individualized treatments and eventually become endophenotypes, 
which can contribute to a new taxonomy of mood disorders (Hellhammer and 
Hellhammer, 2008). 
 
4.2 Exploratory analyses and considerations for future studies 
 
Our exploratory analyses showed positive change for patients across all observed 
Neuropatterns: A decrease in the total score could be observed in the HAMD. A more 
striking finding for future studies of treatment efficacy and/or effectiveness as well as 
treatment selection are the differing frequencies with which these patterns were 
observed in our naturalistic patient sample. The allocation frequencies ranged from zero 
(0%) to 36 (71%) of IG patients. Methods and concepts underpinning treatment 
selection research have made progress (e.g., Cohen and DeRubeis, 2018). Methods to 
plan such studies with appropriate sample sizes, both with view to confirmatory trials 
(sample size calculation/power analysis: Artman et al., 2018) as well as studies in 
naturalistic settings or secondary data analyses (Riley et al., in press a, b) are 
increasingly available. And due to the high number of potential confounding variables 
including social-psychological aspects such as expectations on clinicians' and patients' 
side, and non-specific treatment factors (Lambert, 2013), planning such studies is a 
particular challenge. Understanding the epidemiology of potential moderators and 
mediators of treatment outcomes is therefore crucial for planning (especially 
confirmatory) studies which aim to evaluate the impact of conceptual endophenotypes.  
 
Another key aspect for future studies is the economic viability of the approach. The 
quicker reduction of symptoms of depression in the IG might be an economic argument 
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of using Neuropattern in clinical practice. Since introducing novel diagnostic routines 
and interventions is usually accompanied by additional costs (e.g., materials and staff 
time, for more detail see Hellhammer et al. 2018), the current study suggests that there 
might be scope for recovering (at least some of) the costs of the Neuropattern 
intervention through savings made by insurance companies and employers. Follow-up 
studies should use more detailed instruments to assess the tangible costs of 
depression and shed more light on this aspect. But, this is again an aspect that pertains 
to the field of personalized approaches more generally and has only recently received 
more attention (e.g., Snooks et al., 2018).   
 
4.3  Limitations 
 
Several limitations of this pilot study should be mentioned. Although independently 
allocated, the patients and the treating clinicians were not blinded. The patients knew 
whether they had been included in the treatment as usual (SG) or IG/Neuropattern 
group with the expected better response, expected by both the patients and the 
clinicians. Therefore, we cannot exclude a Hawthorne, Rosenthal and other effect 
related to non-blinding as possible explanation for the between-group effects 
(Jakovljevic, 2014; McCambridge et al., 2014). Such effects nevertheless cannot 
account for the potential specific findings presented in our analysis. Further, the 
patients of both groups shared all therapeutic activities apart from the Neuropattern 
diagnostic and since the time available for patient consultation and ward rounds was 
not changed, the same amount of time was spent in therapeutic activities and 
consultations.  
 
In addition, the study was single-site, it included highly depressed inpatients only (see 
Table 1), and was conducted for no longer than 8 months. Any of these factors might 
have affected the results. Besides replication in different psychiatric settings, studies 
exploring longer time frames or settings with therapies of lower intensity (e.g., 
outpatient psychotherapy) would be instrumental to identify an optimal target population 
for Neuropattern. 
 
All patients received medication at the time of their admission. For patients of the IG, 
Neuropattern led to pharmacological treatment recommendations which might be better 
suited to rebalance potential dysregulations. The physician was free to consider such 
recommendations, particularly if the patient did not respond well to his/her current 
medication, and if there were no other reasons (contraindications, side effects, drug 
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interactions) not to follow the recommendation. In many patients, the medication 
already met the recommendation of Neuropattern. After discharge, patients of both 
groups either continued on these medications, or stopped or replaced pharmacological 
treatments. However, this data set did not provide a sufficiently large size of subgroups 
to run statistical analyses of the effects of treatment recommendations on outcome 
measures. Single case studies may be the best way to learn which patients may 
eventually profit from such recommendations (Smith, 2012). 
 
As with most practice-based studies, it was difficult to pin down exactly the extent to 
which medical personnel adhered to the recommendations, read the individual 
information about the patients, or which recommendations were implemented. Although 
this aspect is commonly encountered in practice-based research (Strauss et al., 2015), 
Neuropattern was mainly devised for primary care settings and focuses on stress-
related pathology. To introduce it into a clinical setting such as a psychiatric hospital 
where acute diseases are treated and which has its own routines made it even more 
important to work towards smoothly integrating the Neuropattern diagnostics in clinical 
practice. 
 
This also constitutes one of the reasons behind the third limitation of this study: The 
Neuropattern system also has a component that assesses biomarkers as part of the 
diagnostic routine (Dallman and Hellhammer, 2011; Hellhammer et al., 2012). Previous 
studies have established that genetic or epigenetic effects play a role in the stress 
system (Cai et al., 2015; Klengel et al., 2014), particularly as related to our measures of 
early adversity. In this study, we were not yet able to test how far Neuropattern 
diagnostic can integrate these biomarkers to optimize the treatment effect. However, 
this has been investigated in two other consecutive studies, which are currently being 
prepared for publication. 
 
4.4    Conclusion  
 
Subtyping depression represents a promising attempt to overcome the lack of 
specificity of many diagnostic constructs and help by optimizing the healing process. 
The results of our study are encouraging, yet we must continue to increase efforts in 
this research domain so that we can move towards evidence-based assessment and 
treatment of depression (Cuijpers et al., 2012).  
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Fig. 1. Flow chart of the chronological steps of the study  
 
Fig. 2. Comparison of the intervention group (IG; Neuropattern, N=67) and standard 
group (SG, N=64) with respect to mean changes in the HAMD scores (error bars 
represent standard errors; *indicates significance by contrast calculation; t0 = baseline, 
t1 – t5 = time points of weekly assessments) 
 
Fig. 3. Comparison of the intervention group (IG; Neuropattern, N=67) and standard 
group (SG, N=64) with respect to mean changes in the Beck’s Depression Inventory 
(BDI), Brief Symptom Inventory (BSI), and short version of the Symptom Check List 
(SCL-K9) for patients with ICD-10 F32 and F33 diagnosis at admission to hospital (pre) 
and discharge from hospital (post); (error bars represent standard errors; t0 = baseline, 






Table 1. Neuropatterns, number of items, and examples of psychological, biological, 
and symptomatic criteria (adapted from Contreras, 2018) 
 
Table 2. Sociodemographic data and descriptive statistics 
 
Table 3. Overview of the components of Neuropattern diagnostics 
  
Table 4. Results of repeated-measures ANOVAs with group and depression diagnosis 
as factor and BDI, BSI, HAMD and SCL-K9 scores as outcome 
 
Table 5. Hamilton Rating Scale for Depression (HAMD) in patients with ICD-10 F32 and 
F33 at t0 and t5 for the different Neuropatterns (total sample size N = 51, patients could 
qualify for more than one Neuropattern) 
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- Diagnosis criteria F32/F33 not  
   fulfilled (n=56) 
- Age > 70 years (n=2) 
Exclusion:  
No participation (n=47) due to: 
- Feeling overwhelmed 
- Added strain 
- No reason / refusal 
Drop-out:  
- Premature discharge (n=1) 








- Retired (n=11) 
- In-patient treatment < 6 weeks (n=13) 
- Unemployed (n=21) 
Patient screening (N= 283) 
Patient inclusion (N= 178) 
Allocation of patients to IG or SG 
Intervention group (IG) with 
Neuropattern diagnostics (nIG= 67) 
ICD-10 F32: 37; F33: 30 
Standard group (SG) with clinical 
standard treatment (nSG= 64) 
ICD-10 F32: 32; F33: 35 
3 month follow up: nSG= 49 3 month follow up: nIG= 59 






Fig. 2. Comparison of the 
(SG; N=64) with respect to mean changes in the HAMD scores (error bars represent 
standard errors; *indicates significance by contrast calculation
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Table 1. Neuropatterns, number of items, and examples of psychological, biological, 
and symptomatic criteria (adapted from Contreras, 2018) 
 
Neuropattern  Psychological 
Variables 
Biological Variables Symptomatic 
Variables 
CRF-hypoactivity 11; lethargy 3; lowered cortisol 
levels upon awakening 
7; hypersomnia 
CRF-hyperactivity 13; anhedonia 5; elevated cortisol 
levels upon awakening 
13; generalized anxiety 
disorder, depression 
CRF-hyperreactivity 7; worried, ruminating 10; strong increase 
of cortisol levels upon 
awakening 
6; Anticipatory stomach 
complaints 
NA-hypoactivity 10; burnout 5; high LF ms² in the 
evening ECG 
7; migraine following 
stress 
NA-hyperactivity 15; tension, drivenness 5; high LF ms² in the 
evening ECG 
12; anxiety disorder 
NA-hyperreactivity 18; irritability 6; high LF ms² in the 
ECG after awakening 
8; emotional sweating 
Serotonin-
hypoactivity 






12; resignation 3; high HF ms² in the 
ECG 
5; reaktive depression 
Cortisol-hypoactivity 10; malaise 4; low levels of cortisol 
after dexamethasone 
8; alternating pain 
Cortisol-hyperactivity 7; fatigue 11; low suppression of 
cortisol after 
dexamethasone 










6; stage fright 5; high LF ms² in the 
morning ECG 
4; sweating under 
physical stress 
GR-resistance 9; exhaustion 0; normal cortisol levels 8; pain 
 
CRF = corticotropin releasing factor, NA = noradrenaline, GR = glucocorticoid receptor,  
HF = high frequency according to spectral analyses of the ECG); LF = low frequency according 
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Table 2. Sociodemographic data and descriptive statistics 
 nIG nSG MIG MSG Test statistics 




t129 = 0.07,  
p = .943 
Gender (m:f) 30:37 32:32   χ² = 0.37,  
p = .600 
Comorbidity:     U = 2108.5,  
z = 0.18,  
p = .855 
one diagnosis 37 31    
two diagnoses 16 25    
three diagnoses 9 5    
> three diagnoses 5 3    
Diagnosis distribution  
(F32 : F33) 
37:30 29:35   χ² = 1.29,  
p = .296 




t129 = 0.50,  
p = .615 
Socio-economic status (based 
on the social class index, 
Winkler et al., 1999)  
    U = 2029,  
z = 0.55,  
p = .584 
lower class 0 1    
lower middle class 3 4    
middle class 7 8    
upper middle class 26 22    
upper class 13 14    
Intangible costs      




















HAMD 67 64    
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M = mean; SE = standard error; Mdn = median; IG = intervention group; SG = standard 
group 
BDI= Beck Depression Inventory; BSI = Brief Symptom Inventory; SCL-K9 = Symptom 




SCL-K9 52 49    






























Direct costs      
Consultations with the doctorpre 
M (SE) 





Consultations with the 
doctor3mth.post 
M (SE) 





Indirect costs      
Days of sick leave pre M (SE); 
Mdn 





Days of sick leave 3mth.post  M 
(SE); Mdn 
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Table 3. Overview of the components of Neuropattern diagnostics  
 
Methods Measures 
Questionnaires Neuropattern Questionnaire 
(NPQ) – Anamnesis (NPQ-A; 
Hellhammer, 2009a) 
 Medical history 
 Vital signs 
 Current diagnosis 
 Past treatment 
 Current medication 
Patient Questionnaire (NPQ-
P; Hellhammer, 2009c) 
Psychological and 
symptomatic variables 
Symptom Lists (NPQ-S; 
Hellhammer, 2009b) 
 Stress-reactivity 
 Exhaustion quality 




Pre- and post-natal adversity 
Patient Health Questionnaire 
(PHQ; Löwe et al., 2002; 
Spitzer et al., 1999) 
Screening for ICD-10 
diagnoses of mental disorders 
Biomarkers  16 saliva samples  
 Low dose (0.25 mg) 
dexamethasone 
suppression test (DST) 
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Table 4. Results of repeated-measures ANOVAs with group and depression diagnosis 
as factor and BDI, BSI, HAMD and SCL-K9 scores as outcome 
 
         F    df  error f        p partial-ƞ2 
BDI      
Main effect           
Time 232.82 1 118 <.001 0.664 
Group 0.42 1 118 .519  
ICD-10 diagnosis F32/F33 1.53 1 118 .219  
Interaction effect           
Time × Group 0.20 1 118 .656  
Time × ICD-10 diagnosis F32/F33 0.01 1 118 .934  
Time × Group × ICD-10 diagnosis F32/F33 5.57 1 118 .020 0.045 
Group × ICD-10 diagnosis F32/F33 0.03 1 118 .865  
BSI           
Main effect           
Time 216.64 1 118 <.001 0.647 
Group 0.13 1 118 .724  
ICD-10 diagnosis F32/F33 0.96 1 118 .330  
Interaction effect           
Time × Group 0.66 1 118 .418  
Time × ICD-10 diagnosis F32/F33 1.83 1 118 .179  
Time × Group × ICD-10 diagnosis F32/F33 6.34 1 118 .013 0.051 
Group × ICD-10 diagnosis F32/F33 0.08 1 118 .773   
HAMD           
Main effect           
Time 96.01 3.69 351.77 < .001 0.503 
Group 0.26 1 95 .609  
ICD-10 diagnosis F32/F33 3.93 1 95 .050  
Interaction effect           
Time × Group 3.14 3.69 351.77 .017 0.032 
Time × ICD-10 diagnosis F32/F33 0.55 3.69 351.77 .688  
Time × Group × ICD-10 diagnosis F32/F33 1.17 3.69 351.77 .325  
Group × ICD-10 diagnosis F32/F33 1.77 1 95 .187  
SCL-K9           
Main effect           
Time 60.47 3.33 322.77 <.001 0.384 
Group 0.06 1 97 .805  
ICD-10 diagnosis F32/F33 0.23 1 97 .635  
Interaction effect           
Time × Group 0.78 3.33 322.77 .517  
Time × ICD-10 diagnosis F32/F33 0.45 3.33 322.77 .735  
Time × Group × ICD-10 diagnosis F32/F33 2.74 3.33 322.77 .038 0.027 
Group × ICD-10 diagnosis F32/F33 0.42 1 97 .519   
 
The effect size partial-ƞ2 is only reported for significant results; BDI = Beck’s 
Depression Inventory, BSI = Brief Symptom Inventory, HAMD = Hamilton Rating Scale 
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Table 5. Hamilton Rating Scale for Depression (HAMD) in patients with ICD-10 F32 and 
F33 at t0 and t5 for the different Neuropatterns (total sample size N = 51, patients could 




               t0               t5 
n                  Mean (SD)                   Mean (SD) 
CRF-hypoactivity 6 26.17 (5.23) 7.83 (3,13) 
CRF-hyperactivity 11 22.00 (7.47) 12.36 (5.61) 
CRF-hyperreactivity 15 22.93 (5.96) 9.13 (6.13) 
NA-hypoactivity 11 25.27 (5.78) 13.91 (5.49) 
NA-hyperactivity 18 24.11 (4.42) 10.06 (5.40) 
NA-hyperreactivity 23 22.78 (7.20) 11.00 (5,74) 
Serotonin-hypoactivity 33 25.12 (4.61) 11.76 (5,32) 
Serotonin-hyperreactivity 36 24.72 (5.06) 11.28 (6.08) 
Cortisol-hypoactivity 3 24.33 (5.13) 8.00 (6.08) 
Cortisol-hyperactivity 0 --- --- 
Sympathetic hyperactivity 4 23.25 (5.68) 13.00 (7.66) 
Sympathetic hyperreactivity 3 19.33 (2.08) 4.67 (2.08) 
GR-resistance 4    23.00 (6.48)  17.00 (5.60) 
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 Neuropattern: Diagnostic tool applying conceptual endophenotypes of stress 
response network 
 Facilitates the detection and treatment of stress-related disorders  
 Faster decline of depression score under Neuropattern based treatment compared 
to standard care in inpatients suffering from major depression. 
 
 
 
 
 
 
 
